亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Use of Iron Chelating Agents in Transfusion Dependent Thalassaemia Major Patients.

医学 脱铁酮 去铁斯若 去铁胺 铁蛋白 内科学 地中海贫血 输血 螯合疗法 血清铁蛋白 胃肠病学 联合疗法 儿科
作者
Soumya Santra,Akash Bhattacharya,Tapan Mukhopadhyay,Dipti Agrawal,Sanjeev Kumar,Padmalaya Das,Paramita Chakrabarty
出处
期刊:PubMed [National Institutes of Health]
卷期号:24 (4): 838-44 被引量:2
链接
标识
摘要

This cross-sectional study was done to find and investigate the utilization pattern of iron chelating agents among 73 transfusion-dependent thalassaemia major patients with continuous enrolment for at least 1 year in a day care treatment centre run by The Thalassaemia Society of India, Kolkata from November 2014 to January 2015. Transfusion dependent thalassaemia major patients above the age of 2 years managed by various haematologists and Thalassaemia specialists were studied. The administration of iron chelators namely Desferrioxamine (DFO), Deferiprone (DFP) and Deferasirox (DFX) were evaluated. Forty seven (64%) of the thalassaemics had serum ferritin level below 2500 ng/dl, of whom 20(27%) patients have ferritin level below 1000ng/dl. A number of 55(75%) of 73 patients who were treated with a single chelating agent consisted 50 patients only on DFX. Exact 8(67%) patients were on DFO+DFP and 4(33%) are treated with DFX+DFP. The mean age was 19 and mean serum ferritin level was 2280 ng/dl among the thalassaemia major patients. DFX was used 68% of patients as monotherapy and 5% patients in combination therapy with DFP. DFX in the dose of 30-40 mg/kg/day was prescribed in 52% of patients. Mean dose of 15 mg/kg/day of DFX was been administered in combination with DFP (75 mg/kg/day) in 5% patients. DFO+DFP were preferred by 8 patients, out of which 6 were aged above 25. Cost of monotherapy is twice that of combination therapy. These data demonstrates the ferritin status and present scenario of utilization of chelating agents among thalassaemia major patients on repeated transfusions. The dosing of new drug, Deferasirox and the cost analysis of various chelating regimen has also been dealt. Individualization rather than rationalization of chelation therapy should be focussed upon in managing iron overload in thalassaemia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
悲凉的问安完成签到,获得积分10
3秒前
天天快乐的应助被科研通管家采纳,获得10
3秒前
369ninja的应助被科研通管家采纳,获得10
3秒前
Jasper的应助被科研通管家采纳,获得10
3秒前
yxl完成签到,获得积分10
6秒前
可耐的盈完成签到,获得积分10
13秒前
绿毛水怪完成签到,获得积分10
19秒前
lsc完成签到,获得积分10
25秒前
成就迎波完成签到,获得积分10
26秒前
单纯的咖啡豆完成签到,获得积分10
31秒前
小fei完成签到,获得积分10
32秒前
李睿杰完成签到,获得积分10
35秒前
白奕完成签到,获得积分10
38秒前
麻辣薯条完成签到,获得积分10
38秒前
清脆晓瑶完成签到,获得积分10
43秒前
时尚身影完成签到,获得积分10
44秒前
49秒前
leoduo完成签到,获得积分0
51秒前
刘刘完成签到,获得积分10
55秒前
如意夏寒完成签到,获得积分10
56秒前
科研通AI6.2的应助被令狐大侠采纳,获得10
57秒前
科研通AI65的应助被令狐大侠采纳,获得10
57秒前
英俊的铭的应助被令狐大侠采纳,获得10
57秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
58秒前
完美世界的应助被令狐大侠采纳,获得10
58秒前
科研通AI6.4的应助被令狐大侠采纳,获得10
58秒前
科研通AI6.2的应助被令狐大侠采纳,获得30
58秒前
58秒前
流苏2完成签到,获得积分10
1分钟前
1分钟前
1分钟前
colin发布了新的文献求助10
1分钟前
1分钟前
鹏1989完成签到,获得积分10
1分钟前
年轻班完成签到,获得积分10
1分钟前
勤劳晋鹏完成签到,获得积分10
1分钟前
1分钟前
colin发布了新的文献求助10
1分钟前
plusweng完成签到 ,获得积分10
1分钟前
LHY完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185137
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834063
捐赠科研通 7782589
什么是DOI,文献DOI怎么找? 3434520
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481206